Radius completes Phase II osteoporosis trial

The Phase II dose-finding study is designed to further evaluate the ability of BA058 to build new bone for the treatment of osteoporosis in postmenopausal women. The randomized, double-blind, placebo- and comparator-controlled Phase II study is evaluating BA058 in 244 otherwise healthy postmenopausal women with osteoporosis at 35 centers in the US, UK, Argentina, and India. The trial evaluates the safety of BA058 across a range of doses as well as its ability to induce bone formation without inducing resorption through measurement of bone formation and resorption markers and by measuring bone mineral density using a number of different modalities.

Radius expects to report the results of the Phase II clinical trial by the end of 2008. Radius also received a second-tranche financing of $28.3 million based on achieving this milestone, for a total second institutional investment of $67.5 million. Radius will use the funds to support development of the company’s four major product candidates.

Richard Lyttle, president and CEO of Radius, said: “We believe that BA058 represents a next-generation bone anabolic treatment for osteoporosis that promises to build bone more rapidly and to be more convenient for patients to use. We look forward to communicating the results later this year.”